The cytoplasmic tail of gp130 contains five tyrosine residues (Y 1 -Y 5 ) that can become phosphorylated after ligand activation of the receptor [6]: the four carboxy-terminal tyrosine residues (Y 2 -Y 5 ) mediate the phosphorylation and activation of STAT3 and STAT1 [6] and the more membrane-proximal Y 1 residue mediates the association and tyrosine phosphorylation of the protein tyrosine phosphatase SHP-2 [6]. In order to determine the contribution of the different tyrosine residues in the receptor to Figure 1 STAT-docking sites on the gp130 cytoplasmic tail are necessary to direct transcriptional induction through the VIP CyRE. NBFL cells (7 × 10 5 cells per 10 cm plate) were transfected by calciumphosphate precipitation with a series of chimeric EGF receptor-gp130 deletion mutants (6 µg) [6] together with Cy1luc (5 µg), which contains the VIP CyRE upstream of a basal RSV promoter driving transcription of the luciferase gene [12] . RSVCAT was used as a control for transfection efficiency. Cells were treated with EGF (5 ng/ml) 12 h after transfection for 36 h before harvesting and analysis of the resultant luciferase and CAT activity. The data shown are the results of 3-5 independent experiments and are expressed as a percentage fold induction of luciferase activity (mean + s.e.m.), with induction by the wild-type EGF receptor being 100%. The differences in luciferase activity between the receptor plasmids are significant (*p < 0.001). 
Results and discussion
The cytoplasmic tail of gp130 contains five tyrosine residues (Y 1 -Y 5 ) that can become phosphorylated after ligand activation of the receptor [6] : the four carboxy-terminal tyrosine residues (Y 2 -Y 5 ) mediate the phosphorylation and activation of STAT3 and STAT1 [6] and the more membrane-proximal Y 1 residue mediates the association and tyrosine phosphorylation of the protein tyrosine phosphatase SHP-2 [6] . In order to determine the contribution of the different tyrosine residues in the receptor to STAT-docking sites on the gp130 cytoplasmic tail are necessary to direct transcriptional induction through the VIP CyRE. NBFL cells (7 × 10 5 cells per 10 cm plate) were transfected by calciumphosphate precipitation with a series of chimeric EGF receptor-gp130 deletion mutants (6 µg) [6] together with Cy1luc (5 µg), which contains the VIP CyRE upstream of a basal RSV promoter driving transcription of the luciferase gene [12] . RSVCAT was used as a control for transfection efficiency. Cells were treated with EGF (5 ng/ml) 12 h after transfection for 36 h before harvesting and analysis of the resultant luciferase and CAT activity. The data shown are the results of 3-5 independent experiments and are expressed as a percentage fold induction of luciferase activity (mean + s.e.m.), with induction by the wild-type EGF receptor being 100%. The differences in luciferase activity between the receptor plasmids are significant (*p < 0.001). 
gp130-mediated regulation of gene expression, we transfected the NBFL neuroblastoma cell line with a series of epidermal growth factor (EGF) receptor-gp130 receptor chimeras composed of the extracellular domain of the EGF receptor fused to various truncations of the cytoplasmic domain of gp130 [6] (Figure 1 ). We assayed gp130-activated gene expression using the luciferase reporter plasmid Cy1luc, which contains the 180 bp cytokine response element (CyRE) of the vasoactive intestinal peptide (VIP) promoter. The CyRE is necessary and sufficient to mediate transcriptional activation of the VIP gene by ciliary neurotrophic factor (CNTF) and leukemia inhibitory factor (LIF) [12] .
Sequential deletion of the carboxy-terminal tyrosines of gp130 gradually reduced EGF-stimulated luciferase activity from Cy1luc ( Figure 1) . Deletion of the Y 2 residue abolished the ability of the chimeric receptor to activate CyRE-mediated transcription ( Figure 1 (Figure 2d ), but retained the ability to mediate phosphorylation of STAT3 (data not shown). Like the unmutated TG chimeric receptor, TGY 2 F could mediate both SHP-2 and STAT3 phosphorylation [6] . Interestingly, in NBFL cells transfected with the TGY 1 F receptor, NT-3 induced a five-fold higher level of luciferase activity than that in cells expressing the unmutated TG receptor (Figure 2a ). Cy1luc induction was not mediated by endogenous TrkC receptors because NT-3 did not induce luciferase activity in the absence of chimeric receptors (data not shown).
NT-3 treatment of cells expressing the mutated TGY 2 F receptor induced luciferase activity to a similar level as that observed for the unmutated TG receptor ( Figure 2a ). All three chimeric receptors were phosphorylated on tyrosine residues in the presence of NT-3, and there was no reproducible difference in either the amount of NT-3-dependent tyrosine phosphorylation or the expression level of the constructs (Figure 2c ,d). These data indicate that phosphorylation of the Y 1 residue normally downregulates gp130-stimulated transcription. The Y 1 residue of the gp130 receptor is only known to be required for SHP-2 tyrosine phosphorylation, suggesting that activated SHP-2 limits the extent of transcriptional stimulation triggered by gp130.
The VIP CyRE is a complex transcriptional element composed of different regions that interact with a variety of transcription factors [12] [13] [14] . To assess directly the relevance of the Y 1 F and Y 2 F mutations on STAT-mediated transcription, NBFL cells were transfected with the TG receptor chimeras and the luciferase reporter plasmid 3(G3)luc, which contains three copies of the VIP CyRE STAT-binding site [12, 14] . Luciferase activity was induced 760-fold upon NT-3 stimulation of the TGY 1 F receptor (Figure 2b ), but only 50-fold by NT-3 stimulation of either the unmutated TG receptor, or the TGY 2 F receptor mutant. Thus, mutation of the Y1 residue results in a dramatic increase in STAT-mediated transcriptional activation, suggesting that recruitment and activation of SHP-2 is involved in the downregulation of STAT-mediated transcription.
NT-3 treatment of NBFL cells transfected with each of the chimeric receptors led to tyrosine phosphorylation of STAT3 (data not shown). Increases in STAT-mediated transcription in cells transfected with the TGY 1 F receptor might result from prolonged phosphorylation of this receptor leading to greater STAT activation over time: such differences were not detected after 10 minutes of NT-3 treatment (data not shown). Indeed, the positive effect of the TGY 1 F mutation on STAT-driven transcription increased with NT-3 treatment up to 36 hours, the longest time point assayed (data not shown). Thus SHP-2, activated by binding to phosphotyrosine motifs on gp130, might dephosphorylate gp130 and/or other proteins important for the JAK-STAT pathway.
We used dominant-negative SHP-2 proteins [15] to examine the effect of inhibiting CNTF-mediated activation of SHP-2 on induction of the VIP CyRE. These mutant SHP-2 proteins associate with gp130 in a CNTF-dependent manner (Figure 3c ) in a similar way to endogenous SHP-2 (data not shown). The dominant-negative SHP-2 proteins contain the Src homology 2 (SH2) domains at the amino terminus of the protein, but lack the phosphatase domain and carboxy-terminal tyrosine residues [10, 15] . Binding of phosphotyrosine residues by the SH2 domains in wild-type SHP-2 is thought to activate its phosphatase activity [16] . The modified SHP-2 proteins act in a dominant-negative manner by competing with endogenous SHP-2 for their 'docking' phosphotyrosines on the cytoplasmic tail of gp130.
NBFL cells cotransfected with a plasmid encoding the dominant-negative SHP-2 protein NP2 (which contains the SHP-2 amino-terminal SH2 domain alone) and the Cy1luc reporter plasmid had approximately seven-fold higher levels of CNTF-stimulated luciferase activity than cells transfected with Cy1luc alone (Figure 3a) . This increase was dose-dependent because increasing amounts of NP2 increased the CNTF-mediated stimulation of luciferase activity from Cy1luc (Figure 3b ). The effect was specific to the SH2 domains of SHP-2 because a plasmid containing either both SH2 domains of the related phosphatase SHP-1 (NCP1, Figure 3a) or the SHP-1 amino-terminal SH2 domain alone (data not shown) did not increase Cy1luc-driven transcription, but instead had a slight inhibitory effect. These data suggest that SHP-2 downregulates gp130-mediated stimulation of VIP gene expression and contrast with previous reports of inhibitory roles for dominant-negative SHP-2 proteins in growth factor/cytokine stimulation of transcription [9, 17, 18] .
Interestingly, the dominant-negative protein NCP2, containing both SHP-2 SH2 domains, increased CNTF-stimulated luciferase activity from Cy1luc to a lesser extent than NP2 (Figure 3a) . Nonetheless, in cells transfected with a plasmid expressing NCP2, luciferase activity from Cy1luc was two-fold greater than in cells transfected with Cy1luc alone. A similar increase was seen in NBFL cells transfected with a plasmid encoding a different dominantnegative SHP-2 protein containing an inactivating cysteine to serine mutation of the essential catalytic cysteine in the phosphatase domain of the full-length protein (data not shown). It is unclear why the SHP-2 amino-terminal SH2 domain alone induces a greater response than both SH2 domains. The amino-terminal SH2 domain of SHP-2 can interact with gp130 ( Figure 3c ). The function of the carboxy-terminal SH2 domain remains unclear, however: it might reduce the affinity of the amino-terminal SH2 domain for the gp130 receptor; alternatively, it might interact with a phosphotyrosine residue on a distinct protein and either regulate a different pathway with opposing actions to that of SHP-2 or sterically hinder the interaction of the SHP-2 amino terminus with the gp130 receptor.
The results from the mutation of the gp130 Y 1 residue and expression of dominant-negative SHP-2 proteins suggest that the presence and activation of SHP-2 normally downregulates gp130-dependent gene expression. Consistent with these data, expression of dominant-negative SHP-2 in primary sympathetic neurons enhances CNTF-induced expression of VIP and another neuropeptide, substance P (T. Servidei and S.A. Reeves, unpublished observations). Also, a mutation in the related leptin receptor OB-R that prevents phosphorylation of SHP-2 upregulates leptinmediated STAT gene induction (L. Carpenter and N.
Stahl, unpublished observations).
A positive regulatory role in signal transduction has previously been assigned to SHP-2, linking various ligand-activated receptors, ranging from the interferon α/β receptor to the insulin receptor, to the activation of the Ras-MAP kinase pathway [10, 11, [18] [19] [20] . In addition, the SHP-2-binding Y 1 residue in gp130, which we found to mediate a negative regulatory role in NBFL cells, has recently been shown to link gp130 to the activation of extracellular signal-regulated kinase 2 (ERK2), through association of SHP-2 and the adaptor molecule Grb2 in BAF-B03 cells [21] . This SHP-2-mediated activation of ERK2 is necessary for gp130-mediated mitogenesis. Thus, the finding that SHP-2 might play a negative role in gp130-regulated gene expression is surprising and suggests that gp130-activated SHP-2 may serve two distinct functions. It is not yet known whether separate domains of SHP-2 are required to elicit these distinct roles, or whether the different pathways diverge further downstream of SHP-2. Our present data support the idea that SHP-2 is a dual-function tyrosine phosphatase that can have positive or negative effects on gene transcription depending on the cell type or target of the signaling pathway in which it acts.
